Emerald Investment Advisers LLC Invests $2.58 Million in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Emerald Investment Advisers acquired 26,459 shares of Dianthus Therapeutics valued at approximately $2.58 million. Institutional investors collectively own 47.53% of DNTH.
• Analysts remain broadly bullish, with an average “Moderate Buy” rating and a consensus price target of $124.27; several firms recently raised their targets to between $122 and $158.
• DNTH opened at $111.10 after gaining 1.5%, but Dianthus reported a quarterly EPS loss of $0.90 versus the expected $0.85 loss. Insiders sold 287,084 shares worth roughly $29.6 million over the past 90 days.

Emerald Investment Advisers LLC acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 26,459 shares of the company's stock, valued at approximately $2,579,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of DNTH. Vanguard Group Inc. lifted its position in shares of Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company's stock worth $84,417,000 after purchasing an additional 406,254 shares during the last quarter. UBS Group AG boosted its stake in Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company's stock valued at $24,999,000 after purchasing an additional 469,547 shares during the period. BNP Paribas Financial Markets boosted its stake in Dianthus Therapeutics by 1,275.3% during the 4th quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company's stock valued at $19,606,000 after purchasing an additional 441,156 shares during the period. SummitTX Capital L.P. grew its holdings in Dianthus Therapeutics by 13.8% in the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company's stock valued at $8,396,000 after buying an additional 12,118 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in Dianthus Therapeutics by 155.5% in the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company's stock valued at $3,406,000 after buying an additional 24,697 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on DNTH shares. HC Wainwright lifted their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Wedbush increased their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Guggenheim reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Truist Financial upped their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $124.27.

Dianthus Therapeutics Stock Up 1.5%

DNTH stock opened at $111.10 on Friday. Dianthus Therapeutics, Inc. has a twelve month low of $22.76 and a twelve month high of $117.88. The company has a market cap of $6.07 billion, a PE ratio of -26.77 and a beta of 1.22. The business's 50-day simple moving average is $100.75 and its 200 day simple moving average is $84.99.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. On average, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Adam M. Veness sold 30,000 shares of the firm's stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the transaction, the senior vice president directly owned 30,000 shares of the company's stock, valued at $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the business's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares in the company, valued at $3,157,086.47. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 287,084 shares of company stock valued at $29,615,923 in the last ninety days. 3.02% of the stock is currently owned by insiders.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source